Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?

Human variability in the kinetics of CYP2D6 substrates has been quantified using a database of compounds metabolised extensively (>60%) by this polymorphic enzyme. Published pharmacokinetic studies (after oral and intravenous dosing) in non-phenotyped healthy adults, and phenotyped extensive (EMs), intermediate or slow-extensive (SEMs) and poor metabolisers (PMs) have been analysed using data for parameters that relate primarily to chronic exposure (metabolic and total clearances, area under the plasma concentration time-curve) and primarily to acute exposure (peak concentration). Similar analyses were performed with the available data for subgroups of the population (age, ethnicity and disease). Interindividual differences in kinetics for markers of oral exposure were large for non-phenotyped individuals and for EMs (coefficients of variation were 67-71% for clearances and 54-63% for C(max)), whereas the intravenous data indicated a lower variability (34-38%). Comparisons between EMs, SEMs and PMs revealed an increase in oral internal dose for SEMs and PMs (ratio compared to EMs=3 and 9-12, respectively) associated with lower variability than that for non-phenotyped individuals (coefficients of variation were 32-38% and 30% for SEMs and PMs, respectively). In relation to the uncertainty factors used for risk assessment, most subgroups would not be covered by the kinetic default of 3.16. CYP2D6-related factors necessary to cover 95-99% of each subpopulation ranged from 2.7 to 4.1 in non-phenotyped healthy adults and EMs to 15-18 in PMs and 22-45 in children. An exponential relationship (R(2)=0.8) was found between the extent of CYP2D6 metabolism and the uncertainty factors. The extent of CYP2D6 involvement in the metabolism of a substrate is critical in the estimation of the CYP2D6-related factor. The 3.16 kinetic default factor would cover PMs for substrates for which CYP2D6 was responsible for up to 25% of the metabolism in EMs.

[1]  E. Sellers,et al.  CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone , 1993, Clinical pharmacology and therapeutics.

[2]  D. Roden,et al.  Stereoselective disposition and pharmacologic activity of propafenone enantiomers. , 1989, Circulation.

[3]  S. Troy,et al.  Pharmacokinetic Interaction Between Multiple‐Dose Venlafaxine and Single‐Dose Lithium , 1996, Journal of clinical pharmacology.

[4]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[5]  W. Potter,et al.  Desipramine pharmacokinetics in Chinese and Caucasian volunteers. , 1984, British journal of clinical pharmacology.

[6]  T. Walle,et al.  Quantitative account of propranolol metabolism in urine of normal man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[7]  C. Masimirembwa,et al.  Genetic Polymorphism of Drug Metabolising Enzymes in African Populations: Implications for the Use of Neuroleptics and Antidepressants , 1997, Brain Research Bulletin.

[8]  A. Renwick.  Data-derived safety factors for the evaluation of food additives and environmental contaminants. , 1993, Food additives and contaminants.

[9]  R. Lefebvre,et al.  Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers , 2000, Clinical pharmacology and therapeutics.

[10]  E. Sellers,et al.  Venlafaxine oxidation in vitro is catalysed by CYP2D6. , 1996, British journal of clinical pharmacology.

[11]  M Schwab,et al.  Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. , 2000, Pharmacogenetics.

[12]  E. Antal,et al.  Estimating Steady State Desipramine Levels in Noninstitutionalized Elderly Patients Using Single Dose Disposition Parameters , 1982, Journal of clinical psychopharmacology.

[13]  L. Bertilsson,et al.  E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.

[14]  D. Roden,et al.  Encainide disposition in patients with renal failure , 1986, Clinical pharmacology and therapeutics.

[15]  R. Bergstrom,et al.  The effect of sertraline on the pharmacokinetics of desipramine and imipramine , 1997, Clinical pharmacology and therapeutics.

[16]  R. Winkle,et al.  Clinical Pharmacology and Antiarrhythmic Efficacy of Encainide in Patients with Chronic Ventricular Arrhythmias , 1981, Circulation.

[17]  S. Troy,et al.  PHARMACOKINETICS OF ONCE-DAILY VENLAFAXINE EXTENDED RELEASE IN HEALTHY VOLUNTEERS , 1997 .

[18]  J. Dorne,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[19]  L. Bertilsson,et al.  Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. , 1999, Pharmacogenetics.

[20]  M. Kendall,et al.  Variability of beta-blocker pharmacokinetics in young volunteers , 2004, European Journal of Clinical Pharmacology.

[21]  P. Lundborg,et al.  The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers , 2004, European Journal of Clinical Pharmacology.

[22]  M. Lennard,et al.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. , 1982, British journal of clinical pharmacology.

[23]  E. Steiner,et al.  Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators , 1987, Clinical pharmacology and therapeutics.

[24]  C. Regårdh,et al.  Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment , 2004, European Journal of Clinical Pharmacology.

[25]  S. Troy,et al.  Pharmacokinetics and Effect of Food on The Bioavailability of Orally Administered Venlafaxine , 1997, Journal of clinical pharmacology.

[26]  M. Eichelbaum,et al.  The genetic polymorphism of sparteine metabolism. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[27]  K Walton,et al.  Pathway-Related Factors: The Potential for Human Data to Improve the Scientific Basis of Risk Assessment , 2001 .

[28]  D Hattis,et al.  Risk evaluation: criteria arising from legal traditions and experience with quantitative risk assessment in the United States. , 1996, Environmental toxicology and pharmacology.

[29]  McLellan Gh.  Letter: SI units. , 1975 .

[30]  P. Beaune,et al.  Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. , 1993, Molecular pharmacology.

[31]  G. Koren,et al.  Intravenous and Oral Propafenone for Treatment of Tachycardia in Infants and Children: Pharmacokinetics and Clinical Response , 1998, Journal of clinical pharmacology.

[32]  U. Hofmann,et al.  Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone , 2000, Clinical pharmacology and therapeutics.

[33]  K. Chiba,et al.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. , 1994, British journal of clinical pharmacology.

[34]  J. Turgeon,et al.  Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. , 1999, Pharmacogenetics.

[35]  A. Setiawati,et al.  Pharmacokinetic and Pharmacodynamic Properties of Controlled Release (CR/ZOK) Metoprolol in Healthy Oriental Subjects: A Comparison with Conventional Formulations of Metoprolol and Atenolol , 1990, Journal of clinical pharmacology.

[36]  J. Turgeon,et al.  Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity , 2000, Clinical pharmacology and therapeutics.

[37]  J. Aitchison,et al.  The Lognormal Distribution. , 1958 .

[38]  W. Cai,et al.  The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. , 1999, British journal of clinical pharmacology.

[39]  C. Regårdh,et al.  Pharmacokinetics of Metoprolol Enantiomers after Administration of the Racemate and the S-Enantiomer as Oral Solutions and Extended Release Tablets , 1993 .

[40]  P. Baumann,et al.  Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes , 1992, Clinical pharmacology and therapeutics.

[41]  R. Rawbone,et al.  Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. , 2000, Toxicology letters.

[42]  P. Dorian,et al.  Influence of Hepatic Dysfunction on the Pharmacokinetics of Propafenone , 1987, Journal of clinical pharmacology.

[43]  R. Huupponen,et al.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol. , 2000, British journal of clinical pharmacology.

[44]  J. Dorne,et al.  Human variability in glucuronidation in relation to uncertainty factors for risk assessment. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[45]  S. R. Howell,et al.  Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. , 1993, Xenobiotica; the fate of foreign compounds in biological systems.

[46]  D. Roden,et al.  Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. , 1989, The Journal of pharmacology and experimental therapeutics.

[47]  M. Lai,et al.  Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes , 1999, Clinical pharmacology and therapeutics.

[48]  D. Roden,et al.  Influence of genetic polymorphism on the metabolism and disposition of encainide in man. , 1984, The Journal of pharmacology and experimental therapeutics.

[49]  A G Renwick,et al.  Human variability and noncancer risk assessment--an analysis of the default uncertainty factor. , 1998, Regulatory toxicology and pharmacology : RTP.

[50]  D. Ciraulo,et al.  Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers , 1988, Clinical pharmacology and therapeutics.

[51]  D. Greenblatt,et al.  Imipramine and desipramine disposition in the elderly. , 1985, The Journal of pharmacology and experimental therapeutics.

[52]  D. Ferry,et al.  Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine , 2004, European Journal of Clinical Pharmacology.

[53]  R. Latini,et al.  Identification of propafenone metaboliser phenotype from plasma and urine excretion data , 2004, European Journal of Clinical Pharmacology.

[54]  R. Jonkers,et al.  Quantification of metoprolol beta 2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling. , 1992, Pulmonary Pharmacology.

[55]  C. Regårdh,et al.  Pregnancy‐induced increase in metoprolol metabolism , 1985, Clinical pharmacology and therapeutics.

[56]  A. Lindgren,et al.  Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[57]  U. Hofmann,et al.  Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. , 1999, Pharmacogenetics.

[58]  U. Meyer,et al.  Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine , 1991, Clinical pharmacology and therapeutics.

[59]  Y. Zhou,et al.  Fluoxetine impairs the CYP2D6‐mediated metabolism of propafenone enantiomers in healthy Chinese volunteers , 1999, Clinical pharmacology and therapeutics.

[60]  R. Winkle,et al.  Propafenone disposition kinetics in cardiac arrhythmia , 1984, Clinical pharmacology and therapeutics.

[61]  P. Edlund,et al.  Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. , 1997, International journal of clinical pharmacology and therapeutics.

[62]  C. Regårdh,et al.  Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study , 2004, European Journal of Clinical Pharmacology.

[63]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[64]  C. Libersa,et al.  Stereoselective Hydroxylation of Mexiletine in Human Liver Microsomes: Implication of P450IID6− A Preliminary Report , 1993, Journal of cardiovascular pharmacology.

[65]  G. Tucker,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE , 1977, The Lancet.

[66]  W. D. Mason,et al.  Food increases the bioavailability of propafenone. , 1987, British journal of clinical pharmacology.

[67]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[68]  Edward V. Sargent,et al.  Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals , 1997 .

[69]  R Truhaut,et al.  The concept of the acceptable daily intake: an historical review. , 1991, Food additives and contaminants.

[70]  S. Faraone,et al.  Absence of Effect of Stimulants on the Pharmacokinetics of Desipramine in Children , 1999, Pharmacotherapy.

[71]  Michael F. Wilson,et al.  Gender‐related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers , 1999, Clinical pharmacology and therapeutics.

[72]  V. John,et al.  The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system. , 1990, American heart journal.

[73]  P. Beaune,et al.  Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.

[74]  M. Chow,et al.  The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine , 1993, Clinical pharmacology and therapeutics.

[75]  J. Turgeon,et al.  Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings , 2000, Clinical pharmacology and therapeutics.

[76]  J. Svensson,et al.  Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. , 1991, British journal of clinical pharmacology.

[77]  M. Eichelbaum,et al.  Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides , 2004, European Journal of Clinical Pharmacology.

[78]  S. Sindrup,et al.  Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine , 1993, European Journal of Clinical Pharmacology.

[79]  Edward V. Sargent,et al.  Establishing Data-Derived Adjustment Factors from Published Pharmaceutical Clinical Trial Data , 1999 .

[80]  W. Cai,et al.  CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. , 1999, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[81]  H. Duff,et al.  Propafenone Disposition in Renal Insufficiency and Renal Failure , 1989, Journal of clinical pharmacology.

[82]  L. Bertilsson,et al.  Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. , 1999, British journal of clinical pharmacology.

[83]  Karen J. Klamerus,et al.  Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite , 1992, Journal of clinical pharmacology.

[84]  H K Kroemer,et al.  Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. , 1991, The Journal of pharmacology and experimental therapeutics.

[85]  S. Otton,et al.  Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype , 1986, Clinical pharmacology and therapeutics.

[86]  S. Troy,et al.  The Influence of Cimetidine on the Disposition Kinetics of the Antidepressant Venlafaxine , 1998, Journal of clinical pharmacology.

[87]  L. Bertilsson,et al.  Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. , 1999, British journal of clinical pharmacology.

[88]  Bruce D. Naumann,et al.  Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients , 1995 .

[89]  J. Biollaz,et al.  Influence of debrisoquin phenotype on the inducibility of propranolol metabolism , 1989, Clinical pharmacology and therapeutics.

[90]  R. Koopmans,et al.  Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. , 1991, The Journal of pharmacology and experimental therapeutics.

[91]  M. Kendall,et al.  The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. , 1982, Biopharmaceutics & drug disposition.

[92]  R. Branch,et al.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.

[93]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[94]  L. Balant,et al.  [Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality]. , 1976, Schweizerische medizinische Wochenschrift.

[95]  D. Roden,et al.  Encainide disposition in patients with chronic cirrhosis , 1986, Clinical pharmacology and therapeutics.

[96]  G. Tucker,et al.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. , 1988, The Journal of pharmacology and experimental therapeutics.

[97]  C. DeVane,et al.  Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers , 2004, European Journal of Clinical Pharmacology.

[98]  W. L. Nelson,et al.  Regioselectivity and Enantioselectivity of Metoprolol Oxidation by Two Variants of cDNA-Expressed P4502D6 , 1995, Pharmaceutical Research.

[99]  A. Capucci,et al.  Relationships Between Debrisoquine Hydroxylation and Propafenone Pharmacokinetics , 1990 .

[100]  D. Roden,et al.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. , 1987, Circulation.

[101]  J. Turgeon,et al.  Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans. , 1993, The Journal of pharmacology and experimental therapeutics.

[102]  K. Yuen,et al.  Pharmacokinetics and comparative bioavailability of two metoprolol tablet preparations , 1996 .

[103]  R. Bergstrom,et al.  Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction , 1992, Clinical pharmacology and therapeutics.

[104]  L. Balant,et al.  Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods. , 1996, Journal of chromatography. B, Biomedical applications.

[105]  S Ohmori,et al.  Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[106]  R. W. Schultz,et al.  The effect of renal disease on the disposition of venlafaxine , 1994, Clinical pharmacology and therapeutics.

[107]  M. Hollmann,et al.  Investigations on the pharmacokinetics of propafenone in man. , 1983, Arzneimittel-Forschung.

[108]  E. Perucca,et al.  Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects , 1993, Therapeutic drug monitoring.

[109]  S. Troy,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of the Potential Drug Interaction Between Venlafaxine and Ethanol , 1995, Journal of clinical pharmacology.

[110]  A. Gérardin,et al.  Comparative pharmacokinetic profiles of metoprolol and chlorthalidone administered alone or in combination to healthy volunteers , 2004, European Journal of Clinical Pharmacology.

[111]  C. Libersa,et al.  Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. , 1990, Biochemical pharmacology.

[112]  M. Ingelman-Sundberg,et al.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine , 2004, European Journal of Clinical Pharmacology.

[113]  I. Blair,et al.  Structural characterization of urinary metabolites of the antiarrhythmic drug encainide in human subjects. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[114]  K Walton,et al.  Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[115]  M. Hollmann,et al.  Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. , 1988, Methods and findings in experimental and clinical pharmacology.

[116]  D. Zhong,et al.  Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[117]  B. Burlew,et al.  Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[118]  C. Funck-Brentano,et al.  Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. , 1993, British journal of clinical pharmacology.

[119]  M. Eichelbaum,et al.  Influence of the defective metabolism of sparteine on its pharmacokinetics , 1979, European Journal of Clinical Pharmacology.

[120]  S. Troy,et al.  The Pharmacokinetics of Venlafaxine When Given in a Twice‐Daily Regimen , 1995, Journal of clinical pharmacology.

[121]  U. Gundert-Remy,et al.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.

[122]  V. Parker,et al.  Effects of Age and Gender on Venlafaxine and O‐Desmethylvenlafaxine Pharmacokinetics , 1996, Pharmacotherapy.

[123]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[124]  S. Troy,et al.  Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers , 1997 .

[125]  L. Bertilsson,et al.  Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine , 1998, Clinical pharmacology and therapeutics.

[126]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[127]  K Walton,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[128]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.

[129]  E. Perucca,et al.  Phenobarbital induces the 2-hydroxylation of desipramine. , 1996, Therapeutic drug monitoring.

[130]  K Walton,et al.  Default Factors for Interspecies Differences in the Major Routes of Xenobiotic Elimination , 2001 .

[131]  R. Lins,et al.  Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers. , 1996, International journal of clinical pharmacology and therapeutics.

[132]  Pi Eh,et al.  Pharmacokinetics of desipramine in Caucasian and Asian volunteers. , 1986 .

[133]  T Ishizaki,et al.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. , 1995, British journal of clinical pharmacology.

[134]  J. Azuma,et al.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. , 1999, British journal of clinical pharmacology.

[135]  U. Hofmann,et al.  Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans , 1995, Clinical pharmacology and therapeutics.